Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | HTR1A | P08908 | 7/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4865321 | 0.94 | DRD2 (0.59) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL4868327 | 0.94 | DRD2 (0.62) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL4865241 | 0.78 | DRD2 (0.59) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL4867270 | 0.76 | ADRA1D (0.54) | SLC6A4 | |
| SCHEMBL11264673 | 0.76 | KDM4E (0.51) | DRD2KDM4ELMNAHTR1AHTR2A | |
| SCHEMBL11315106 | 0.75 | KDM4E (0.81) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL11223590 | 0.75 | KDM4E (0.73) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL4482017 | 0.75 | KDM4E (0.73) | DRD2KDM4ELMNAALOX15HTR1A | |
| Hydrochloric Acid SCHEMBL11313113 | 0.75 | KDM4E (0.81) | DRD2KDM4ELMNAALOX15HTR1A | |
| SCHEMBL11267488 | 0.73 | HTR1A (0.51) | DRD2KDM4ELMNAHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | claimed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | claimed |
| US-7148235-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2006-12-12 | — | — | US | claimed |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-10-27 | — | — | US | claimed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | claimed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332506-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2007-03-01 | — | — | US | disclosed |
| US-7148235-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2006-12-12 | — | — | US | disclosed |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-10-27 | — | — | US | disclosed |
| US-6939870-B2 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH (US) | 2005-09-06 | — | — | US | disclosed |
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | WYETH | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204402-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | DRD2 25/4885KDM4E 1002/4885LMNA 2568/4885 |
| US-20050239775-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | DRD2 23/4885KDM4E 827/4885LMNA 2036/4885 |
| US-20070049582-A1 | Substituted-3-indolyl-4-piperidino-alkyl heterocycles for the treatment of depression | TPH1, TPH2, HTR1A | DRD2 23/4885KDM4E 827/4885LMNA 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.